Fig. 3: ERBB signaling in SCaBER and J82 bladder cancer cells upon TKI treatment and EGF stimulation.
From: EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
a Western blot analyses illustrate activation and inhibition of EGFR/p-EGFR (Tyr1068, Tyr1045), ERK/p-ERK (Thr202,Tyr204), and p-AKT (Ser473) 24 h after EGF and erlotinib treatment. DMSO application was used as untreated control. β-actin (for EGFR) and tubulin (for ERK) served as loading controls. b–i Relative mRNA expression of ERBB receptors (EGFR, ERBB2, ERBB3, and ERBB4), ERBB ligands (AREG, EREG, and HB-EGF) and the EGFR target gene SOX9 normalized to corresponding DMSO control 24 h after EGF and/or erlotinib treatment for SCaBER and J82 bladder cancer cells. GAPDH was used for standardization. FC: fold change. Vertical lines: +standard error of mean (SEM) of triplicates.
